Drug Profile
Asparaginase PEGylated biosimilar - Nanogen Biopharmaceutical
Alternative Names: Pegylated L-asparaginase - NanogenLatest Information Update: 16 Jan 2022
Price :
$50
*
At a glance
- Originator Nanogen Biopharmaceutical Co
- Class Amidohydrolases; Antineoplastics
- Mechanism of Action Asparagine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for research development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in Vietnam (IM, Injection)
- 28 Apr 2018 No recent reports of development identified for research development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in Vietnam (IV, Injection)
- 20 Mar 2014 Early research in Acute lymphoblastic leukaemia in Vietnam (IM)